Hubei Huazhong Pharmaceutical Co. Ltd.

Primary objective: To evaluate the efficacy of the experimental drug pimavanserin tartrate capsules in the treatment of patients with Parkinson's disease and psychotic symptoms. Secondary objective: To evaluate the safety of the experimental drug pimavanserin tartrate capsules in the treatment of patients with Parkinson's disease and psychotic symptoms.

According to the relevant provisions of bioequivalence test, doxycycline hydrochloride tablets (trade name: Vibramycin, specification: 100mg (calculated as C22H24N2O8)) of Pfizer Japan Inc. as the licensee were selected as the reference preparation, and the test preparation doxycycline hydrochloride tablets (specification: 0.1g) produced and provided by Huazhong Pharmaceutical Co., Ltd. were subjected to human bioequivalence test for fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation doxycycline hydrochloride tablets (specification: 0.1g) and the reference preparation doxycycline hydrochloride tablets (trade name: Vibramycin, specification: 100mg (calculated as C22H24N2O8)) by healthy volunteers.

To investigate whether there are differences in the extent and rate of absorption between a single oral dose of the test preparation ticagrelor tablets (Huazhong Pharmaceutical Co., Ltd., specification: 90 mg) and the reference preparation ticagrelor tablets (trade name: Brilinta®, AstraZeneca Pharmaceuticals Co., Ltd., specification: 90 mg) in healthy participants on an empty stomach, to evaluate the bioequivalence of the test preparation and the reference preparation when administered in the fasting state, and to observe the safety of the test preparation and the reference preparation in healthy participants.